Adcetris
brentuximab vedotin · CD30Three xenograft models from human HL and ALCL cell lines
Enhertu: animal efficacy model or human cells?
fam-trastuzumab deruxtecan · HER2
Efficacy evidence
HER2-positive breast cancer xenograft mouse models (e.g., KPL-4 in nude mice)
“The anti-tumor activity of DS-8201a was evaluated in several mouse models of breast cancer. In a mouse xenograft model of HER2-positive breast cancer, the activity of a single dose of 10 mg/kg DS-8201a or MAAL-9001 was evaluated 13 days after inoculation of KPL-4 cells to female CAnN.Cg-Foxn1nu/CrlCrlj nude mice”
Why that model
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reviewer's view of the efficacy data
CHMP: PDX data suggest efficacy incl. T-DM1-refractory tumours, but lower effect than lower-DAR comparator in one model was unexpected
“Results in patient-derived xenograft (PDX) models of breast cancer suggest that DS-8201a is effective even in T-DM1 refractory HER2-expressing breast cancer tumours due to the drug-linker system with a different mechanism of action. However, it is unexpected that DS-8201a has a clear, although not significant, lesser effect than MAAL-9002b which has a two times lower drug-to-antibody ratio (DAR) in the HER2-positive CTG-0708 model.”
Same question, other ADCs
Besponsa
inotuzumab ozogamicin · CD22Subcutaneous xenograft and systemically disseminated ALL mouse models
Datroway
datopotamab deruxtecan · Trop-2Nude mouse xenografts of human pancreatic cancer, NSCLC and breast cancer
Decnupaz
pivekimab sunirine · CD123Two BPDCN patient-derived xenograft (PDX) models in NSG mice
Elahere
mirvetuximab soravtansine · FRαOvarian cancer xenograft mouse models (single IV dose)
Emrelis
telisotuzumab vedotin · c-Metc-Met-positive NSCLC cell line-derived and patient-derived xenograft mouse models
Kadcyla
ado-trastuzumab emtansine · HER2HER2+ xenografts (BT-474 EI, Calu-3) and MMTV-HER2 transgenic tumor model; growth inhibition in all three at 3 to 31 mg/kg
Mylotarg
gemtuzumab ozogamicin · CD33CD33+ HL-60 leukemia xenograft in mice: >80% tumor growth inhibition
Padcev
enfortumab vedotin · Nectin-4Nectin-4-expressing patient-derived bladder cancer xenografts (AG-B1, AG-B8) in mice: >75% tumor growth inhibition
Polivy
polatuzumab vedotin · CD79bHuman DLBCL and B-cell lymphoma xenografts in mice; in vitro Ramos cytotoxicity
Tivdak
tisotumab vedotin · Tissue factorCervical cancer patient-derived xenograft (PDX) models in mice
Trodelvy
sacituzumab govitecan · Trop-2Mouse xenografts bearing human Trop-2-expressing tumours
Zynlonta
loncastuximab tesirine · CD19CD19-positive human Burkitt lymphoma (Ramos, Daudi) and DLBCL (WSU-DLCL2) xenografts in immunodeficient mice